BALA CYNWYD, PA / ACCESSWIRE / January 2, 2020 / Brodsky & Smith, LLC reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and other violations of federal and state law with respect to proposed acquisition transactions. If you own shares of any of the below-referenced stocks and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, or calling toll free 877-534-2590. There is no cost or financial obligation to you.
CONTINENTAL BUILDING PRODUCTS, INC. (NYSE:CBPX)
Under the terms of the agreement, Continental shareholders will receive only $37.00 for each share of Continental common stock owned. The investigation concerns whether the Continental Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Saint-Gobain SA is underpaying for the Company. The transaction may undervalue the Company and would result in a substantial loss for many Continental shareholders. For example, the stock traded above the deal consideration as recently as September 2018.
Additional information can be found at http://www.brodskysmith.com/cases/continental-building-products-inc-nyse-cbpx/,, or call 877-534-2590. No cost or obligation to you.
AUDENTES THERAPEUTICS, INC. (NasdaqGS:BOLD)
Under the terms of the agreement, Audentes shareholders will receive only $60.00 for each share of Audentes common stock owned. The investigation concerns whether the Audentes Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Astellas Pharma, Inc.is underpaying for the Company. The transaction may undervalue the Company. For example, the merger will provide Astellas with Audentes robust pipeline, including its lead program AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM).
Additional information can be found at http://www.brodskysmith.com/cases/audentes-therapeutics-inc-nasdaqgs-bold/, or call 877-534-2590. No cost or obligation to you.
SYNTHORX, INC. (NasdaqGS:THOR)
Under the terms of the agreement, Synthorx shareholders will receive only $68.00 for each share of Synthorx common stock owned. The investigation concerns whether the Synthorx Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Sanofi is underpaying for the Company. For example, the drug at the center of the deal is Synthorx's investigational medicine code-named THOR-707. Meant to treat solid tumors, the drug is designed to boost the number of cancer-fighting cells in the body, potentially overwhelming the disease with effector T-cells and natural killer cells.
Additional information can be found at http://www.brodskysmith.com/cases/synthorx-inc-nasdaqgs-thor/, or call 877-534-2590. No cost or obligation to you.
Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
SOURCE: Brodsky & Smith, LLC